"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
MeSH Number(s)
D02.455.426.392.368.242.888.777
D02.455.849.291.850.777
Concept/Terms
Anzatax- Anzatax
- Bull Brand of Paclitaxel
Taxol- Taxol
- Taxol A
- Bristol-Myers Squibb Brand of Paclitaxel
- Bris Taxol
- Bristol-Myers Brand of Paclitaxel
Praxel- Praxel
- Lemery Brand of Paclitaxel
Onxol- Onxol
- Ivax Brand of Paclitaxel
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in Harvard Catalyst Profiles by year, and whether "Paclitaxel" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 2 | 6 |
1995 | 8 | 4 | 12 |
1996 | 9 | 5 | 14 |
1997 | 7 | 5 | 12 |
1998 | 6 | 9 | 15 |
1999 | 20 | 8 | 28 |
2000 | 13 | 11 | 24 |
2001 | 11 | 17 | 28 |
2002 | 13 | 16 | 29 |
2003 | 14 | 12 | 26 |
2004 | 7 | 10 | 17 |
2005 | 19 | 21 | 40 |
2006 | 16 | 25 | 41 |
2007 | 15 | 10 | 25 |
2008 | 19 | 19 | 38 |
2009 | 17 | 17 | 34 |
2010 | 23 | 19 | 42 |
2011 | 23 | 21 | 44 |
2012 | 13 | 25 | 38 |
2013 | 15 | 30 | 45 |
2014 | 19 | 20 | 39 |
2015 | 22 | 26 | 48 |
2016 | 16 | 21 | 37 |
2017 | 18 | 27 | 45 |
2018 | 19 | 18 | 37 |
2019 | 18 | 30 | 48 |
2020 | 22 | 17 | 39 |
2021 | 19 | 28 | 47 |
2022 | 3 | 27 | 30 |
2023 | 4 | 26 | 30 |
2024 | 1 | 5 | 6 |
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial. JAMA. 2024 03 26; 331(12):1015-1024.
-
Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy. Biomacromolecules. 2024 Mar 11; 25(3):1800-1809.
-
The End of a Controversy: The Rise, Fall, and Redemption of Paclitaxel-Coated Devices. Am J Cardiol. 2024 Apr 01; 216:43-45.
-
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clin Cancer Res. 2024 02 16; 30(4):767-778.
-
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3ß Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clin Cancer Res. 2024 02 01; 30(3):522-531.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.
-
Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ann Vasc Surg. 2024 Apr; 101:164-178.
-
Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study. ORL J Otorhinolaryngol Relat Spec. 2024; 86(1):41-49.
-
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer. Mol Cancer Ther. 2023 Nov 01; 22(11):1304-1318.
-
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). J Clin Oncol. 2024 Jan 10; 42(2):170-179.